

# ChronoBiology References

Spring 2014—Issue 17

## Blastocystis: A Question of Pathogenicity

Carrie C. McMillin, ND

1. Tan K. New Insights on Classification, Identification, and Clinical Relevance of Blastocystis spp. *Clin Microbio Rev.* 2008;21(4):639.
2. Abe, N. Molecular and phylogenetic analysis Blastocystis isolates from various hosts. *Ver Parasitol.* 2004;20:235-242.
3. Noel C, Dufernes F, Gerbod D, et al. Molecular phylogenies of Blastocystis isolates from different hosts: implications for genetic diversity, identification of species, and zoonosis. *J Clin Microbiol.* 2005;43:348-355.
4. Clark C. Extensive genetic diversity in Blastocystis hominis. *Mol Biochem Parasitol.* 1997;87:79-83.
5. Huang D, White A. An updated review on Cryptosporidium and Giardia. *Gastroenterol Clin N Am.* 2006;35:291-314.
6. Kuhls T, Mosier D, Crawford D, Griffis J. Seroprevalence of cryptosporidial antibodies during infancy, childhood, and adolescence. *Clin Infect Dis.* 1994;18:731-735.
7. Cavalier-Smith T. A revised six-kingdom system of life. *Biol Rev Camb Philos Soc.* 1998;73:203-266.
8. Böhm-Gloning B, Knobloch J, Walderich B. Five subgroups of Blastocystis hominis from symptomatic and asymptomatic patients revealed by restriction site analysis of PCR-amplified 16S-like rDNA. *Trop Med Int Health.* 1997;2:771-778.
9. Kaneda Y, Horiki N, Cheng X, et al. Ribodemes of Blastocystis hominis isolated in Japan. *Am J Trop Med Hyg.* 2001;65:393-396.
10. Wong K, Ng G, Lin R, et al. Predominance of subtype 3 among Blastocystis isolates from a major hospital in Singapore. *Parasitol Res.* 2008;102:663-670.
11. Yoshikawa H, Wu Z, Howe J, et al. Polymerase chain reaction-based genotype classification among human Blastocystis hominis populations isolated from different countries. *Parasitol Res.* 2004;92:22-29.
12. Jelinek T, Peyerl G, Löscher T, et al. The role of Blastocystis hominis as a possible intestinal pathogen in travelers. *J Infect.* 1997;35:63-66.
13. Tan K. Blastocystis in humans and animals: new insights using modern methodologies. *Vet Parasitol.* 2004;126:121-144.
14. Blastocystis spp. FAQs. Centers for Disease Control and Prevention Website. <http://www.cdc.gov/parasites/blastocystis/faqs.html>. Updated January 6, 2012. Accessed February 3, 2014.
15. Brites C, Barberino M, Bastos M, et al. Blastocystis hominis as a potential cause of diarrhea in AIDS patients: a report of six cases in Bahia, Brazil. *Braz J Infect Dis.* 1997;1:91-94.
16. Cirioni O, Giacometti A, Drenaggi D, et al. Prevalence and clinical relevance of Blastocystis hominis in diverse patient cohorts. *Eur J Epidemiol.* 1999;15:389-393.
17. Gassama A, Sow P, Fall F, et al. Ordinary and opportunistic enteropathogens associated with diarrhea in Senegalese adults in relation to human immunodeficiency virus serostatus. *Int J Infect Dis.* 2001;5:192-198.
18. Noureldin M, Shaltout A, El Hamshary E, Ali M. Opportunistic intestinal protozoal infections in immunocompromised children. *J Egypt Soc Parasitol.* 1999;29:951-961.
19. El-Shazly A, Abdel-Magied A, El-Beshbishi S, et al. Blastocystis hominis among symptomatic and asymptomatic



- individuals in Talkha Center, Dakahlia Governorate, Egypt. *J Egypt Soc Parasitol*. 2005;35:653-666.
20. Graczyk T, Shiff C, Tamang L, et al. The association of Blastocystis hominis and Endolimax nana with diarrheal stools in Zambian school-age children. *Parasitol Res*. 2005;98:38-43.
  21. Kaya S, Cetin E, Aridogan B, et al. Pathogenicity of Blastocystis hominis, a clinical reevaluation. *Turkiye Parazitoloj Derg*. 2007;31:184-187.
  22. Leelayoova S, Rangsin R, Taamasri P, et al. Evidence of waterborne transmission of Blastocystis hominis. *Am J Trop Med Hyg*. 2004;70:658-662.
  23. Miller S, Rasario C, Rojas E, Scorza J. Intestinal parasitic infection and associated symptoms in children attending day care centres in Trujillo, Venezuela. *Trop Med Int Health*. 2003;8:342-347.
  24. Özcakir O, Güreser S, Ergüven S, et al. Characteristics of Blastocystis hominis infection in a Turkish university hospital. *Turkiye Parazitoloj Derg*. 2007;31:277-282.
  25. Diseases and Conditions: Blastocystis hominis infection. Mayo Clinic website. <http://www.mayoclinic.org/diseases-conditions/blastocysts-hominis/basics/definition/con-20026572>. Published January 25, 2013. Accessed February 3, 2014.
  26. Blastocystis hominis. Stanford University website. [http://www.stanford.edu/group/parasites/ParaSites2010/Delamon\\_Alfredo\\_Rego/paraSITEfinalweb.htm](http://www.stanford.edu/group/parasites/ParaSites2010/Delamon_Alfredo_Rego/paraSITEfinalweb.htm). Published Unknown. Accessed February 3, 2014.
  27. Garavelli P. The therapy of blastocystosis. *J Chemother*. 1991;3(Suppl 1):245-246.
  28. Diaczok B, Rival J. Diarrhea due to Blastocystis hominis: an old organism revisited. *South Med J*. 1987;80:931-932.
  29. Armentia A, Medez J, Gomez A, et al. Urticaria by Blastocystis hominis. Successful treatment with paromomycin. *Allergol Immunopathol*. 1993;21:149-151.
  30. Chen T, Chan C, Chen H, et al. Clinical characteristics and endoscopic findings associated with Blastocystis hominis in healthy adults. *Am J Trop Med Hyg*. 2003;69:213-216.
  31. Hu K, Lin C, Wang T, et al. Amoebic liver abscess or is it? *Gut*. 2008;57:627,683.
  32. Giacometti A, Cirioni O, Fiorentini A, et al. Irritable bowel syndrome in patients with Blastocystis hominis infection. *Eur J Clin Microbiol Infect Dis*. 1999;18:436-439.
  33. Yakoob J, Jafri W, Jafri N, et al. Irritable bowel syndrome: in search of an etiology: role of Blastocystis hominis. *Am J Trop Med Hyg*. 2004;70:383-385.
  34. Udkow M, Markell E. Blastocystis hominis: prevalence in asymptomatic versus symptomatic hosts. *J Infect Dis*. 1993;168:242-244.
  35. Nigro L, Larocca L, Massarelli L, et al. A placebo-controlled treatment trial of Blastocystis hominis infection with metronidazole. *J Travel Med*. 2003;10:128-130.
  36. Rossignol J, Kamil S, Said M, et al. Effect of nitazoxanide in persistent diarrhea and enteritis associated with Blastocystis hominis. *Clin Gastroenterol Hepatol*. 2005;3:987-991.
  37. Ok U, Girginkardesler N, Balcioglu C, et al. Effect of trimethoprim-sulfamethaxazole in Blastocystis hominis infection. *Am J Gastroenterol*. 1999;94:3245-3247.
  38. Hawrelak, J. Session Six Notes: Blastocystis. Health Masters Live: The Natural Gastrointestinal Masterclass. Jan 2014. <http://www.healthmasterslive.com/product/the-natural-gastrointestinal-masterclass>.
  39. Yang L, Singh M, Yap E, et al. In vitro response of Blastocystis hominis against traditional Chinese medicine. *Journal of Ethnopharmacology*. 1996;55:35-42.
  40. Su S, Chen G, Zhang R, et al. The Trichomonocidal Effect of Nine Chinese Herbs on the Blastocystis hominis. *Lishizhen Medicine and Materia Medica Research*. 2007;03.
  41. Zhang X, Qiao J, Zhang R, et al. In vitro antiprotozoal effects of Brucea javanica, Coptis chinensis, Radix pulsatillae and Arecae on Blastocystis hominis. *Journal of Tropical Medicine*. 2007;11.
  42. Yakoob J, Abbas Z, Beg MA, et al. In vitro sensitivity of Blastocystis hominis to garlic, ginger, white cumin, and black pepper used in diet. *Parasitology Research*. 2011;109:379-385.
  43. Dinleyici EC, Eren M, Dogan N, et al. Clinical efficacy of Saccharomyces boulardii or metronidazole in symptomatic children with Blastocystis hominis infection. *Parasitology Research*. 2011;108:541-545.
  44. Versalovic J. Manual of Clinical Microbiology. 3rd ed. Washington, DC: American Society for Microbiology Press; 2011.
  45. McHardy I, Wu M, Shimizu-Cohen R, et al. Detection of Intestinal Protozoa in the Clinical Laboratory. *J Clin Microbiol*. 2014;52(3):712.
  46. Tille P. Bailey & Scott's Diagnostic Microbiology. 13th ed. St. Louis, MO: Elsevier Mosby; 2014.



## The Therapy Corner: The Anxiety-Depression Spectrum

### Brandy Webb, ND

1. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distribution of DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry*. 2005;62(6):593.
2. Kayton W, Ciechanowski P. Panic disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis. UpToDate.com. Aug 2013.
3. Lamers F, van Oppen P, Comijs HC, et al. Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands Study of Depression and Anxiety (NESDA). *J Clin Psychiatry*. 2011 Mar;72(3):341-8.
4. Cope EC, Levenson CW. Role of zinc in the development and treatment of mood disorders. *Curr Opin Clin Nutr Metab Care*. 2010 Nov;13(6):685-9.
5. American Psychiatric Association: Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition, 2010. <http://psychiatryonline.org/guidelines.aspx> (Accessed on April 17, 2012).
6. Parikh SV, Segal ZV, Grigoriadis, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. *J Affect Disord*. 2009;117 Suppl 1:S15.
7. Gartlehner G, Hansen RA, Morgan LC, et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. *Ann Intern Med*. 2011 Dec;155(11):772-85.
8. Katon W, Ciechanowski P. Unipolar major depression in adults: choosing initial treatment. UpToDate. Feb 2014.
9. Young SN. Folate and depression--a neglected problem. *J Psychiatry Neurosci*. 2007 Mar;32(2):80-2.
10. Chaitow L, Bradley D, Gilbert C. *Multidisciplinary Approaches to Breathing Pattern Disorders*. Churchill Livingstone. 2002.
11. Damas-Mora J, Davies L, Taylor W, Jenner FA. Menstrual respiratory changes and symptoms. *Br J Psychiatry*. 1980 May;136:492-7.
12. Chaitow L. Breathing pattern disorders, motor control, and low back pain. *Journal of Osteopathic Medicine*. 2004;7(1):34-41.
13. Lee H, Ohno M, Ohta S, Mikami T. Regular moderate or intense exercise prevents depression-like behavior without change of hippocampal tryptophan content in chronically tryptophan-deficient and stressed mice. *PLoS One*. 2013 Jul 4;8(7):e66996.
14. Herring MP, O'Connor PJ, Dishman RK. The effect of exercise training on anxiety symptoms among patients: a systematic review. *Arch Intern Med*. 2010;170(4):321.
15. Katon W. Unipolar major depression in adults: Choosing initial treatment. UpToDate. Jan 2014.
16. Rethorst CD, Trivedi MH. Evidence-based recommendations for the prescription of exercise for major depressive disorder. *J Psychiatr Pract*. 2013 May;19(3):204-12.
17. Goldstein AN, Greer SM, Saletin JM, et al. Tired and apprehensive: anxiety amplifies the impact of sleep loss on aversive brain anticipation. *J Neurosci*. 2013 Jun 26;33(26):10607-15.
18. Sadler P, McLaren S, Jenkins M. A psychological pathway from insomnia to depression among older adults. *Int Psychogeriatr*. 2013 Aug;25(8):1375-83.
19. van Praag HM. In search of the mode of action of antidepressants: 5-HTP/tyrosine mixtures in depression. *Adv Biochem Psychopharmacol*. 1984;39:301-14.
20. Meltzer HY, Perline R, Tricou BJ, et al. Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders. II. Relation to suicide, psychosis, and depressive symptoms. *Arch Gen Psychiatry*. 1984 Apr;41(4):379-87.
21. Ma Z, Zhang G, Jenney C, et al. Characterization of serotonin-toxicity syndrome (toxidrome) elicited by 5-hydroxy-L-tryptophan in clorgyline-pretreated rats. *Eur J Pharmacol*. 2008 Jul 7;588(2-3):198-206.
22. Jussofie A, Schmiz A, Hiemke C. Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. *Psychopharmacology*. 1994 Dec;116(4):469-474.
23. Martin HB, McCallum M, Stofer WD, Eichinger MR. Kavain attenuates vascular contractility through inhibition of calcium channels. *Planta Med*. 2002 Sep;68(9):784-9.
24. Cott JM. In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract. *Pharmacopsychiatry*. 1997 Sep;30 Suppl 2:108-12.



25. Müller WE, Rolli M, Schäfer C, Hafner U. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. *Pharmacopsychiatry*. 1997 Sep;30 Suppl 2:102-7.
26. Waksman JC, Hard K, Jolliff H, et al. Serotonin syndrome associated with the use of St. John's wort (*hypericum perforatum*) and paroxetine. *J Toxicol Clin Toxicol*. 2000;38(5):521.

